Takeda Chief Transformation Officer Files Form 144 for $634K in ADSs
TAKEDA PHARMACEUTICAL CO LTD
Subscribe to track TAK
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Form 144 Notice of Proposed Sale Issuer: Takeda Pharmaceutical Company Limited ($TAK) Insider: Lauren Rusckowski Duprey (Chief Transformation Officer) Proposed Sale Amount: 34,535 ADSs (~$634,407.95) Approx. Sale Date: September 10, 2026 Broker: Interactive Brokers LLC
Comprehensive Analysis
Executive Summary
On September 10, 2026, Lauren Rusckowski Duprey, Chief Transformation Officer at Takeda Pharmaceutical Company Limited (TAK), filed a Form 144 notice disclosing the proposed sale of 34,535 American Depositary Shares (ADSs) with an estimated aggregate market value of $634,407.95 (~$18.37 per ADS).
Transaction Details
- Security: American Depositary Shares (ADSs)
- Shares Proposed for Sale: 34,535
- Aggregate Market Value: $634,407.95
- Approximate Sale Date: September 10, 2026
- Broker: Interactive Brokers LLC
- Origin of Securities: Vested Restricted Stock Unit (RSU) awards acquired on July 30, 2024, as equity compensation from the issuer.
Prior 3-Month Activity
- Date: July 13, 2026
- Shares Sold: 47,586 ADSs
- Gross Proceeds: $813,720.60
- Remarks: Executed to satisfy tax withholding obligations related to share vesting effective July 13, 2026.
Market Impact Assessment
With 198,318,946 units outstanding, the proposed sale represents less than 0.02% of outstanding shares. Given the standard nature of post-vesting equity dispositions, this transaction carries low trading significance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.